{"nctId":"NCT03280056","briefTitle":"Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients","startDateStruct":{"date":"2017-08-28","type":"ACTUAL"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"count":196,"armGroups":[{"label":"NurOwn® (MSC-NTF cells)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: NurOwn® (MSC-NTF cells)","Other: Bone Marrow aspiration"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo","Other: Bone Marrow aspiration"]}],"interventions":[{"name":"NurOwn® (MSC-NTF cells)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Bone Marrow aspiration","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\n* Having onset of ALS disease symptoms, including limb weakness within 24 months at the Screening Visit.\n* ALSFRS-R ≥ 25 at the screening Visit.\n* Upright slow vital capacity (SVC) measure ≥ 65% of predicted for gender, height, and age at the screening Visit.\n* Rapid progressors\n* Participants taking a stable dose of Riluzole are permitted in the study\n* Citizen or permanent resident of the United States or Canadian citizen able to travel to a US site for all follow-up study visits\n\nExclusion Criteria:\n\n* Prior stem cell therapy of any kind\n* History of autoimmune or other serious disease (including malignancy and immune deficiency) that may confound study results\n* Current use of immunosuppressant medication or anticoagulants (per Investigator discretion)\n* Exposure to any other experimental agent or participation in an ALS clinical trial within 30 days prior to Screening Visit\n* Use of RADICAVA (edaravone injection) within 30 days of screening or intent to use edaravone at any time during the course of the study including the follow up period\n* Use of non-invasive ventilation (BIPAP), diaphragm pacing system or invasive ventilation (tracheostomy)\n* Feeding tube\n* Pregnant women or women currently breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Proportion of NurOwn® Treated Participants With a ≥1.25 Points/Month Improvement in Post-treatment Slope vs. Pre-treatment Slope in ALSFRS-R Score at 28 Weeks Following the First Treatment as Compared to Placebo","description":"The ALSFRS-R is a quickly administered (10 minutes) ordinal, validated rating scale (ratings 0-4) used to determine participants' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, as measured by quantitative neuromuscular strength testing, and with quality of life measures, and predicted survival. The total score of ALSFRS-R ranges from 0-48, with higher score being better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Whose Disease Progression is Halted or Improved as Measured by a 100% or Greater Improvement in Post-treatment Slope vs. Pre-treatment Slope in ALSFRS-R Score of NurOwn® Treatment vs. Placebo","description":"The ALSFRS-R is a quickly administered (10 minutes) ordinal, validated rating scale (ratings 0-4) used to determine participants' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, as measured by quantitative neuromuscular strength testing, and with quality of life measures, and predicted survival. The total score of ALSFRS-R ranges from 0-48, with higher score being better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Score of NurOwn® (MSC-NTF Cells) Treated Patients vs. Placebo Treated Patients as Measured by Change From Baseline in ALSFRS-R Score at Week 28","description":"The ALSFRS-R is a quickly administered (10 minutes) ordinal, validated rating scale (ratings 0-4) used to determine participants' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, as measured by quantitative neuromuscular strength testing, and with quality of life measures, and predicted survival. The total score of ALSFRS-R ranges from 0-48, with higher score being better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.52","spread":"0.670"},{"groupId":"OG001","value":"-5.88","spread":"0.665"}]}]}]},{"type":"SECONDARY","title":"NurOwn® (MSC-NTF Cells) Treated Patients vs. Placebo Treated Patients as Measured by the Combined Assessment of Function and Survival at 28 Weeks","description":"The combined Assessment of Function and Survival (CAFS) is a composite endpoint based on (1) the change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) score and (2) time to death.\n\nOn the ALSFRS-R, 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a total score range (minimum and maximum score) of 0-48 (sum of all 12 items). The higher the score the better functioning. For the survival endpoint, the longer time the better outcome.\n\nA patient's CAFS score represents a patient's rank in the study based on comparing the patient's outcome for both the change in ALSFRS-R and the time to death to all other patients in the study in a pairwise fashion. The ranked scores range from 001 to 189 (the number of subjects in the mITT population) with larger rank score numbers associated with a better outcome. The reported values are the mean rank scores in each group for the composite endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.74","spread":"5.210"},{"groupId":"OG001","value":"72.21","spread":"4.890"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":95},"commonTop":["Procedural pain","Headache","Back pain","Fall","Procedural headache"]}}}